SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.71
-0.60 (-4.87%)
As of 2:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.31
Open12.33
Bid11.70 x 4000
Ask11.91 x 1400
Day's Range11.52 - 12.36
52 Week Range5.52 - 18.23
Volume67,477
Avg. Volume80,301
Market Cap205.204M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • The travel industry is extremely resilient, says Expedia CEO
    CNBC Videos3 months ago

    The travel industry is extremely resilient, says Expedia CEO

    Expedia President and CEO Mark Okerstrom joins "Squawk on the Street" to discuss the company's strong earnings and what the state of travel is for the United States and around the world.

  • Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
    Zacks14 days ago

    Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 62.34% and 517.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire14 days ago

    Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

    CAMBRIDGE, Mass., May 09, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Expedia Shares Fall as Home-Rental Business Vrbo Goes Slow
    Bloomberg21 days ago

    Expedia Shares Fall as Home-Rental Business Vrbo Goes Slow

    Wall Street was looking for $2.69 billion, according to data compiled by Bloomberg. Revenue growth from Vrbo slowed to 14 percent. Bellevue, Washington-based Expedia has been struggling to chase rivals Airbnb Inc. and Booking Holdings Inc. in the fast-growing and lucrative market for short-term rentals with its HomeAway and Vrbo services.

  • Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for
    Zacks21 days ago

    Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for

    Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire22 days ago

    Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Spero (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $11.18 per share, which is equal to the closing price of Spero’s common stock on April 30, 2019.  Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates.  The options are subject to the terms and conditions of Spero’s 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

  • Marriott Is Officially Getting Into the Homesharing Business
    Skift24 days ago

    Marriott Is Officially Getting Into the Homesharing Business

    Marriott, the world’s largest hotel company with more than 7,000 hotels around the world, is officially getting into the homesharing business with the launch of Homes & Villas by Marriott International in 100 destinations. A year after it began conducting a homesharing pilot, the 91-year-old hotel group appears convinced it can compete with travel disruptors […] The post Marriott Is Officially Getting Into the Homesharing Business appeared first on Skift.

  • GlobeNewswirelast month

    Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

    CAMBRIDGE, Mass., April 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Spero Gets Fast Track Designation for SPR994, Shares Improve
    Zacks2 months ago

    Spero Gets Fast Track Designation for SPR994, Shares Improve

    Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.

  • GlobeNewswire2 months ago

    Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

    CAMBRIDGE, Mass., March 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire2 months ago

    Spero Announces Appointment of Cynthia Smith to its Board of Directors

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced the appointment of Cynthia Smith to its Board of Directors, effective as of today. “We are pleased to welcome Cynthia to our Board of Directors,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • Will Spero Therapeutics Continue to Surge Higher?
    Zacks2 months ago

    Will Spero Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Spero Therapeutics.

  • Business Wire2 months ago

    Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review

    Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19

  • Associated Press2 months ago

    Airbnb, HomeAway lose legal challenge to Santa Monica rules

    Short-term rental sites Airbnb and HomeAway lost a legal challenge Wednesday against an ordinance enacted by a popular California tourist city. The ordinance imposed several obligations involving rental sites in seaside Santa Monica, including refraining from booking properties that are not licensed and listed on a city registry. A 9th U.S. Circuit Court of Appeals panel ruled that a lower court properly dismissed the legal challenge over its failure to state a claim against the city.

  • Airbnb Loses Major Fight Over California City's Rental Law
    Bloomberg2 months ago

    Airbnb Loses Major Fight Over California City's Rental Law

    The ruling Wednesday by a three-judge panel of the Ninth Circuit is a setback for the home-sharing platforms in their effort to avoid regulation by cities that blame the rapid proliferation of short-term rentals for a shortage of affordable housing and a disintegration of residential communities. The Santa Monica ordinance holds the companies responsible for booking rentals of residences that aren’t licensed by the city. San Francisco-based Airbnb is the largest home-rental platform with more than 6 million listings around the world.

  • GlobeNewswire3 months ago

    Spero Therapeutics to Present at March Investor Conferences

    Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.  Spero has begun start-up activities for the ADAPT-PO Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections and anticipates opening trial sites to support study enrollment in the first quarter of 2019. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of non-tuberculous mycobacterial (NTM) infections.  In January 2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy subjects and expects top-line data from this trial in the second half of 2019.

  • GlobeNewswire3 months ago

    Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

    CAMBRIDGE, Mass., Feb. 26, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?
    Simply Wall St.3 months ago

    Are Spero Therapeutics, Inc.’s (NASDAQ:SPRO) Interest Costs Too High?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Spero Therapeutics, Inc. (NASDAQ:SPRO), which has zero-debt on its balanceRead More...

  • Expedia Analysts Grow More Bullish After Strong Earnings
    Bloomberg3 months ago

    Expedia Analysts Grow More Bullish After Strong Earnings

    While growth in Expedia’s home rental service disappointed, the company made up for it with strength in its core platform. Cowen also sees positive read-through to peers Booking Holdings Inc. and TripAdvisor Inc., which report later this month. “HomeAway was the major disappointment” in the fourth quarter and the lack of prior warning from management suggested it must have started to deteriorate at the end of the year, after third-quarter results.

  • Expedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Expedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript

    EXPE earnings call for the period ending December 31, 2018.

  • Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates
    Bloomberg3 months ago

    Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates

    Adjusted earnings before interest, tax, depreciation and amortization, will grow 10 percent to 15 percent in 2019, Chief Financial Officer Alan Pickerill said on a conference call Thursday. Analysts were projecting an increase of 9 percent, according to data compiled by Bloomberg. Analysts were looking for signs that Expedia’s performance would justify a runaway share price so far this year.

  • GlobeNewswire4 months ago

    Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

    “With the FDA’s acceptance of our IND application for SPR994, we are excited to continue our Phase 3 initiation efforts, including opening clinical trial sites for enrollment in the U.S.," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • GlobeNewswire4 months ago

    Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

    “SPR720 is a promising drug candidate that has the potential to become the first approved oral treatment for NTM infections. NTM infections cause chronic, debilitating disease and represent an area of high unmet need as there are no specifically approved orally administered treatment options,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. The Phase 1 clinical trial evaluating SPR720 is a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...